ReviewCurrent osteoporosis reports2025
Chronic Kidney Disease-Mineral and Bone Disorder Management in 4D: The Case for Dynamic Treatment Regime Methods to Optimize Care.
Review in Current osteoporosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Letter to the editor regarding: 'Hypocalcemia following denosumab in osteoporosis: Incidence and risk factors in a Saudi cohort'.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Multimodal Detection of Subclinical Cardiovascular Disease in Chronic Kidney Disease.Cardiorenal medicine · 2026Review
- Microneedle-based transdermal delivery systems for metabolic bone diseases: advances, challenges, and future perspectives.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewChronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a complex condition impacting patients with kidney failure and characterized by inter-related features such as hyperparathyroidism, hyperphosphatemia, and hypocalcemia. Current treatments include active vitamin D sterols, calcimimetics, and phosphate binders alone and in combination. However, identifying optimal treatment is challenged by interdependency among CKD-MBD features, requiring new approaches to understand dynamic systems. In this review, we discuss challenges and opportunities for a more integrated view of CKD-MBD care. RECENT
findingsFew clinical studies in CKD-MBD care have incorporated a dynamic understanding of the disorder and its treatment. Dynamic treatment regime methods are an evolving area of artificial intelligence (AI) that offer a promising approach for modeling and understanding CKD-MBD care. Efforts to date have included dynamic systems and quantitative systems pharmacology-based models to simulate the impact of alternative treatment regimes. Additional studies utilizing dynamic treatment regime approaches may help improve knowledge gaps in CKD-MBD care. Although preliminary research highlights the potential of dynamic treatment regime approaches in optimizing CKD-MBD management, further investigation and clinical validation are necessary to fully harness this approach for improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.